Objective: To analyze the phenotypic and functional characteristics of endothelial (T3A) cells derived from human hepatocellular cell carcinoma.
Methods: Endothelial cells were isolated from human hepatocellular carcinoma specimens. The identification of T3A cells was performed by checking von Willebrand Factor (vWF), CD31, CD34 and Dil-Ac-LDL uptake. The cell surface fenestrations, a specific morphological feature of tumor derived EC, were investigated by scanning and transmission electron microscopy. The phenotypic characteristics of T3A cells were analyzed by fluorescence-activated cell sorter (FACS) and were further conformed by real-time PCR at transcription level. Furthermore, tumor necrosis factor alpha (TNFalpha)-induced cytotoxicity was evaluated by 3-(4, 5-dimethythiazolyl) -2, -diphenyl-2H-tetrazolium-bromide (MTT) assay; Matrix metalloproteinase secretion was detected by zymography; Angiogenic ability in vitro was analyzed by culturing T3A cells in three-dimensional Matrigel plug. Coagulant and fibrinolytic activities were detected by enzyme-linked immunosorbent assay (ELISA).
Results: The isolated T3A cells exhibited classic "spindle-shape" morphology and monolayer growth and contact inhibition properties. Immunofluorescent staining showed that T3A cells expressed vWF, CD31, CD34, and uptake of Dil-Ac-LDL at a high level. The cell surface fenestrations were observed on T3A cells by scanning and transmission electron microscopy. By FACS and real-time PCR, T3A cells were found to express alphav3, alphavbeta5 and TNF receptor p75 at high levels, and TNF receptor p55 and ICAM-1 at low levels, as compared with those in human liver sinusoidal endothelial cells (LSEC). In response to TNFalpha, LSEC exhibited a dose-dependent cytotoxicity, while T3A cells were resistant. Gelatin zymography showed that MMP-2 activity was higher in T3A cells than that in LSEC. In a three-dimensional plug of Matrigel, T3A cells exhibited stronger angiogenic ability as compared with LSEC. In addition, T3A cells released more tissue factor (TF), tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor (PAI-1) and urine plasminogen activator (u-PA) than LSEC in response to TNFalpha.
Conclusion: Tumor-derived endothelial cells are phenotypically and functionally different from those derived from normal liver tissue.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Chromophobe Renal Cell Carcinoma With Extensive Retraction Artifact: A Potential Diagnostic Pitfall From Micropapillary Urothelial Carcinoma.
Int J Surg Pathol
April 2024
Department of Anatomic Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.
Article Synopsis
- Chromophobe renal cell carcinoma (RCC) can display various morphological patterns, but a new subtype resembling upper urothelial tract micropapillary carcinoma (MPC) has been identified, marked by extensive stromal retraction.
- A study reviewed 12 nephrectomies of MPC-like chromophobe RCC, predominantly affecting older men, with tumors averaging 6.4 cm, and a diverse range of pathological stages.
- Molecular testing revealed a high prevalence of chromosomal losses and mutations in notable genes, yet follow-up indicated that patients generally showed no evidence of disease, emphasizing the importance of recognizing this variant to prevent misdiagnosis.
Biphasic papillary (biphasic squamoid alveolar) renal cell carcinoma: a clinicopathologic and molecular study of 17 renal cell carcinomas including 10 papillary adenomas.
Virchows Arch
March 2024
Department of Pathology, Stanford University, Stanford, CA, USA.
Article Synopsis
- Biphasic papillary renal cell carcinoma (PRCC) is a rare subtype of PRCC with less than 70 reported cases, characterized by a biphasic morphology that includes squamoid features.
- This study analyzed 17 cases of biphasic PRCC, finding that the average age was 62 years, with a slight male predominance, and most tumors were confined to the kidney, though a few exhibited metastasis.
- Immunohistochemical analysis revealed that biphasic PRCC tumors show strong expression of specific markers like PAX8 and keratin 7, and about a third of cases had mutations in the MET gene, indicating a potential for further research into their molecular characteristics and behavior.
A Laparoscopically Treated Case of Peritoneal Dissemination Mimicking Liver Metastases from Distal Cholangiocarcinoma Four Years After the Initial Pancreaticoduodenectomy.
Anticancer Res
April 2023
Department of Surgery, Yamaga City Medical Center, Kumamoto, Japan.
Background/aim: Operable peritoneal dissemination from distal cholangiocarcinoma after pancreaticoduodenectomy is rare. Furthermore, peritoneal dissemination mimicking liver metastasis has scarcely been reported.
Case Report: An 81-year-old woman received pancreaticoduodenectomy for distal cholangiocarcinoma.
The osteoclast-type giant cell rich carcinoma of urinary bladder: A case series.
Pathol Res Pract
November 2022
Department of Pathology, University of Pittsburgh, PA, USA. Electronic address:
Background: Osteoclast-type giant cell-rich carcinomas (OGCRCs) of urinary bladder are extremely rare, aggressive tumors that are often diagnosed as undifferentiated carcinomas. The morphology overlaps with other giant cell-rich benign and malignant bladder lesions. Little is known about the pathogenesis and clinical management of this aggressive variant.
View Article and Find Full Text PDFAdjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
October 2022
Department of Urology, The Royal Free London NHS Foundation Trust, University College London Division of Surgery and Interventional Science, London, UK; The Netherlands Cancer Institute, Amsterdam, Netherlands.
Background: The standard of care for locoregional renal cell carcinoma is surgery, but many patients experience recurrence. The objective of the current study was to determine if adjuvant atezolizumab (vs placebo) delayed recurrence in patients with an increased risk of recurrence after resection.
Methods: IMmotion010 is a randomised, double-blind, multicentre, phase 3 trial conducted in 215 centres in 28 countries.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!